Prostatype Genomics AB
STO:PROGEN
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.0125
0.2252
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
Abbvie Inc
NYSE:ABBV
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Realty Income Corp
NYSE:O
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Relative Value
The Relative Value of one PROGEN stock under the Base Case scenario is 0.028 SEK. Compared to the current market price of 0.019 SEK, Prostatype Genomics AB is Undervalued by 33%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
PROGEN Competitors Multiples
Prostatype Genomics AB Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| SE |
P
|
Prostatype Genomics AB
STO:PROGEN
|
18.8m SEK | 18.4 | -0.5 | -0.4 | -0.4 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
341.5B USD | 6.2 | 64.5 | 15.7 | 24.1 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
180.5B USD | 5.8 | 57.7 | 20.2 | 36.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
129B USD | 9.6 | 29.8 | 26.2 | 29 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
123.6B USD | 12 | -252.2 | 26.8 | 28.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
105B USD | 3.8 | 99.7 | 9.5 | 12 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 1 975 | -504 | -548.8 | -534.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
142.3B AUD | 6.5 | 36.4 | 22.3 | 27.8 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 19 | -58.3 | -62.8 | -56.7 | |
| US |
P
|
Palatin Technologies Inc
LSE:0KF3
|
38.5B USD | 6 513.5 | -1 169.6 | -1 185.3 | -1 173.1 | |
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
35.2B USD | 15 | -483 | 212.6 | 327.3 |
You don't have any saved screeners yet
